LivingGLP1
Study S001135

A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity

Registration

Registration
NCT07357766
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
QUADRUPLE
Status
WITHDRAWN
Enrollment
0
Start
2026-06-22
Primary completion
2027-11-29
Lead sponsor
Novo Nordisk A/S
Conditions
Overweight; Obesity
Interventions
DRUG:Cagrisema; DRUG:Placebo CagriSema
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
OTHER:U1111-1317-0133; OTHER:2024-520448-41

Registered primary outcomes

  • Relative change in body weight [From baseline (week 0) to end of treatment (week 44)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.